AB Science Narrows Focus, Discontinues Non-Priority Trials — AB Science S.A.

Event summary

AB Science is discontinuing three non-priority clinical trials to focus resources on two key programs: AB8939 for acute myeloid leukemia (AML) and masitinib for amyotrophic lateral sclerosis (ALS).
The discontinued studies include Phase 2 of masitinib in mast cell activation syndrome, Phase 3 of masitinib in mastocytosis, and Phase 3 of masitinib in progressive multiple sclerosis.
The company completed Phase 1, Step 3 of the AB8939 program for AML and seeks authorization to initiate Phase 4, evaluating a triple combination with venetoclax and azacitidine.
The ALS study (AB23005) will be updated and resubmitted for regulatory approval after protocol revisions.

The big picture

AB Science’s decision to streamline its clinical pipeline reflects a strategic pivot toward high-potential programs amid competitive pressures in oncology and neurology. The move aligns with broader industry trends of focused resource allocation as biopharma companies navigate regulatory hurdles and seek differentiation in crowded markets.

What we're watching

Regulatory Timelines: The pace at which AB Science secures authorization for Phase 4 of the AML study and resumes the ALS trial will determine its near-term development trajectory.
Execution Risk: Whether AB Science can successfully transition resources to prioritized programs without disrupting ongoing studies or regulatory relationships.
Competitive Positioning: How the focus on AML and ALS impacts its standing in these therapeutic areas, particularly against established and emerging treatments.